1,748 results on '"Scheen, A. J."'
Search Results
2. Cardiovascular and renal effects of the combination therapy of a GLP-1 receptor agonist and an SGLT2 inhibitor in observational real-life studies
3. Paradoxical real-life underuse of GLP-1 receptor agonists in type 2 diabetes patients with atherosclerotic cardiovascular disease: Underuse of GLP-1RAs in patients with ASCVD
4. Metformin, Sulfonylureas, DPP-4 Inhibitors and Cardiovascular Outcomes in Type 2 DM
5. Cardiovascular protection significantly depends on HbA1c improvement with GLP-1RAs but not with SGLT2 is in type 2 diabetes: A narrative review
6. Real-life underuse of SGLT2 inhibitors for patients with type 2 diabetes at high cardiorenal risk
7. Similar incidence of stroke with SGLT2 inhibitors and GLP-1 receptor agonists in real-world cohort studies among patients with type 2 diabetes
8. Double et triple agonistes : rôle du glucagon
9. Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke ? Discordance between randomised controlled trials and observational studies
10. Comparative effects between old and new antidiabetic agents on metabolic- associated fatty liver disease (MAFLD)
11. Use of SGLT2 inhibitors after bariatric/metabolic surgery: Risk/benefit balance
12. Metabolic disorders induced by psychotropic drugs
13. Cardiovascular and renal outcomes with SGLT2 inhibitors: Real-life observational studies in older patients with type 2 diabetes: SGLT2 inhibitors in elderly and real life
14. Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes
15. Efficacy and safety profile of SGLT2 inhibitors in the elderly: How is the benefit/risk balance?
16. Clinical pharmacology of antidiabetic drugs: What can be expected of their use?
17. Glucagon, from past to present: a century of intensive research and controversies
18. Glucose-lowering agents and risk of ventricular arrhythmias and sudden cardiac death: A comprehensive review ranging from sulphonylureas to SGLT2 inhibitors
19. Antidiabetic agents and risk of atrial fibrillation/flutter: A comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists
20. Dissecting the reduction in cardiovascular death with SGLT2 inhibitors: Potential contribution of effects on ventricular arrhythmias and sudden cardiac death?
21. When therapeutic drugs lead to diabetes
22. Lower-limb amputations in patients treated with SGLT2 inhibitors versus DPP-4 inhibitors: A meta-analysis of observational studies
23. Acute renal injury events in diabetic patients treated with SGLT2 inhibitors: A comprehensive review with a special reference to RAAS blockers
24. Lower limb amputations: protection with GLP-1 receptor agonists rather than increased risk with SGLT2 inhibitors?
25. Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile
26. Médicaments anti-obésité : leçons des échecs pour l’avenir
27. The diuretic effects of SGLT2 inhibitors: A comprehensive review of their specificities and their role in renal protection
28. Efficacy / safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes
29. Statins and clinical outcomes with COVID-19: Meta-analyses of observational studies
30. Epidemiology of acute kidney injury adverse events with SGLT2 inhibitors: A meta-analysis of observational cohort studies
31. Could metformin modulate cardiovascular outcomes differently with DPP-4 inhibitors compared with SGLT2 inhibitors?
32. DPP-4 inhibition and COVID-19: From initial concerns to recent expectations
33. Sulphonylureas in the management of type 2 diabetes: To be or not to be?
34. Obésité et COVID-19 : le choc fatal entre deux pandémies
35. Series: Implications of the recent CVOTs in type 2 diabetes: Impact on guidelines: The endocrinologist point of view
36. Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
37. Pharmacokinetic/Pharmacodynamic Properties and Clinical Use of SGLT2 Inhibitors in Non-Asian and Asian Patients with Type 2 Diabetes and Chronic Kidney Disease
38. Sodium–glucose co-transporter type-2 inhibitors for hospitalised patients with COVID-19: safe but not protective
39. Cardiovascular protection significantly depends on HbA1c improvement with GLP-1RAs but not with SGLT2 is in type 2 diabetes: a narrative review
40. Real-life underuse of SGLT2 inhibitors for patients with type 2 diabetes at high cardiorenal risk
41. Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists
42. Place des inhibiteurs des SGLT2 dans le traitement du patient diabétique de type 2
43. Similar incidence of stroke with SGLT2 inhibitors and GLP-1 receptor agonists in real-world cohort studies among patients with type 2 diabetes
44. Pharmacokinetic, toxicological, and clinical considerations for the treatment of type 2 diabetes in patients with liver disease: a comprehensive update
45. Cardiovascular outcome studies with incretin-based therapies: Comparison between DPP-4 inhibitors and GLP-1 receptor agonists
46. L'épopée des insulines des années 1930 aux années 1980
47. Underuse of glucose-lowering medications associated with cardiorenal protection in type 2 diabetes: from delayed initiation to untimely discontinuation
48. The current role of SGLT2 inhibitors in type 2 diabetes and beyond: a narrative review
49. Traitement pharmacologique du diabète de type 2 après chirurgie bariatrique/métabolique
50. Cibler la voie métabolique du cortisol comme action thérapeutique dans le diabète de type 2
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.